

Screening period (-72 h to Day 0)

- Assess for study eligibility
- Perform screening laboratory assessment
- Obtain informed consent

Randomisation 1:1 (Day 1)

Stratified for the following factors:

- Tumour (known distant metastasis, no distant metastasis, haematological malignancy)
- Geographical region (four separate regions)
- Known history of previously diagnosed VTE (yes or no)

**Tinzaparin 175 IU/kg once daily
(N=450)**

**Warfarin once daily (target INR 2.0–3.0)
overlapping with initial tinzaparin 175
IU/kg once daily (5–10 days) (N=450)**

Treatment period (Day 1 to Day 180)

- Scheduled visits on Days 1, 7, 14, 30, 60, 90, 120, 150 and 180
- From Day 30, patients will be contacted by telephone 14 days after each monthly visit
- From Day 30, patients withdrawn from study treatment will be followed up by telephone in place of scheduled monthly visits

Follow-up period (Day 181 to Day 210)